Trial Profile
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants [Extension of 700024351]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary)
- Indications Gastroenteritis; Rotavirus infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 08 Sep 2013 New trial record
- 08 Sep 2013 New trial record
- 08 Sep 2013 New trial record